Celsion (CLSN) EPS Estimated At $-0.31; Seritage Growth Properties Class A (SRG) Shorts Up By 0.58%

February 24, 2018 - By Richard Conner

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.31 EPS on March, 15.They anticipate $1.65 EPS change or 84.18% from last quarter’s $-1.96 EPS. After having $-0.39 EPS previously, Celsion Corporation’s analysts see -20.51% EPS growth. The stock decreased 3.11% or $0.07 during the last trading session, reaching $2.18. About 201,154 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since February 24, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Seritage Growth Properties Class A (NYSE:SRG) had an increase of 0.58% in short interest. SRG’s SI was 9.58 million shares in February as released by FINRA. Its up 0.58% from 9.53 million shares previously. With 347,900 avg volume, 28 days are for Seritage Growth Properties Class A (NYSE:SRG)’s short sellers to cover SRG’s short positions. The SI to Seritage Growth Properties Class A’s float is 44.77%. The stock increased 0.29% or $0.12 during the last trading session, reaching $41.1. About 197,579 shares traded. Seritage Growth Properties (NYSE:SRG) has declined 7.48% since February 24, 2017 and is downtrending. It has underperformed by 24.18% the S&P500.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $38.66 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. On Thursday, October 5 the stock rating was upgraded by Maxim Group to “Buy”. The company was maintained on Tuesday, August 15 by Maxim Group. Oppenheimer initiated Celsion Corporation (NASDAQ:CLSN) rating on Monday, November 20. Oppenheimer has “Buy” rating and $9.0 target. The rating was downgraded by Maxim Group on Thursday, November 10 to “Hold”. Zacks upgraded it to “Hold” rating and $2.50 target in Wednesday, August 12 report. The stock has “Hold” rating by Maxim Group on Thursday, June 1. The stock of Celsion Corporation (NASDAQ:CLSN) has “Buy” rating given on Friday, August 7 by Cantor Fitzgerald. Maxim Group maintained the stock with “Hold” rating in Monday, August 7 report. The firm earned “Buy” rating on Tuesday, January 19 by Maxim Group.

Seritage Growth Properties is a real estate investment trust. The company has market cap of $2.36 billion. It invests in the real estate markets of United States. It currently has negative earnings. The firm is engaged in the acquisition, ownership, development, redevelopment, management and leasing of diversified retail real estate.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: